Researchers analyzed the effectiveness of two heart failure (HF) risk scores, Meta-Analysis Global Group in Chronic HF (MAGGIC-HF) risk score and the model of the Barcelona Bio-HF Risk Calculator (BCN-Bio-HF), in predicting mortality in advanced heart failure patients treated with levosimendan. Researchers used data from the Levo-D registry for this study.
It involved 403 patients from 23 Spanish hospitals, primarily older men with reduced left ventricular ejection fraction and ischaemic heart disease. The results showed that both risk scores underestimated the 1-year mortality rate, with suboptimal accuracy in prediction. This research highlights the need for more specific risk assessment tools for advanced heart failure patients.
Ref: Codina P, Dobarro D, de Juan-Bagudá J, et al. Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry. ESC Heart Fail. 2023;10(5):2875-2881. doi:10.1002/ehf2.14400